메뉴 건너뛰기




Volumn 74, Issue 6, 2015, Pages 1124-1131

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

(175)  Maurer, Britta a   Graf, Nicole b   Michel, Beat A a   Müller Ladner, Ulf c   Czirják, László d   Denton, Christopher P e   Tyndall, Alan f   Metzig, Carola g   Lanius, Vivian g   Khanna, Dinesh h   Distler, Oliver a   Tarner, Ingo H c   Cerinic, Marco Matucci i   Guiducci, Serena i   Walker, Ulrich f   Lapadula, Giovanni j   Iannone, Florenzo j   Becvar, Radim k   Sierakowsky, Stanislaw l   Bielecka, Otylia Kowal l   more..


Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; CREATINE KINASE;

EID: 84932632017     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205226     Document Type: Article
Times cited : (104)

References (22)
  • 1
    • 0027729083 scopus 로고
    • Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies
    • Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
    • (1993) J Rheumatol , vol.20 , pp. 1892-1896
    • Clements, P.J.1    Lachenbruch, P.A.2    Seibold, J.R.3
  • 2
    • 77956631231 scopus 로고    scopus 로고
    • Evidence-based management of rapidly progressing systemic sclerosis
    • Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010;24:387-400.
    • (2010) Best Pract Res Clin Rheumatol , vol.24 , pp. 387-400
    • Khanna, D.1    Denton, C.P.2
  • 3
    • 0029048089 scopus 로고
    • Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis
    • Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
    • (1995) J Rheumatol , vol.22 , pp. 1281-1285
    • Clements, P.1    Lachenbruch, P.2    Siebold, J.3
  • 4
    • 68049111578 scopus 로고    scopus 로고
    • Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials
    • Amjadi S, Maranian P, Furst DE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490-8.
    • (2009) Arthritis Rheum , vol.60 , pp. 2490-2498
    • Amjadi, S.1    Maranian, P.2    Furst, D.E.3
  • 5
    • 34547485497 scopus 로고    scopus 로고
    • Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model
    • Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56:2422-31.
    • (2007) Arthritis Rheum , vol.56 , pp. 2422-2431
    • Shand, L.1    Lunt, M.2    Nihtyanova, S.3
  • 6
    • 34547743765 scopus 로고    scopus 로고
    • Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase i antibody
    • Perera A, Fertig N, Lucas M, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007;56:2740-6.
    • (2007) Arthritis Rheum , vol.56 , pp. 2740-2746
    • Perera, A.1    Fertig, N.2    Lucas, M.3
  • 7
    • 33847394965 scopus 로고    scopus 로고
    • Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis
    • Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 2007;46:442-5.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 442-445
    • Nihtyanova, S.I.1    Brough, G.M.2    Black, C.M.3
  • 8
    • 0033064099 scopus 로고    scopus 로고
    • High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
    • Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
    • (1999) Arthritis Rheum , vol.42 , pp. 1194-1203
    • Clements, P.J.1    Furst, D.E.2    Wong, W.K.3
  • 9
    • 65249109216 scopus 로고    scopus 로고
    • Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial
    • Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:1102-11.
    • (2009) Arthritis Rheum , vol.60 , pp. 1102-1111
    • Khanna, D.1    Clements, P.J.2    Furst, D.E.3
  • 10
    • 33750367940 scopus 로고    scopus 로고
    • Minimally important difference in diffuse systemic sclerosis: Results from the D-penicillamine study
    • Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-9.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1325-1329
    • Khanna, D.1    Furst, D.E.2    Hays, R.D.3
  • 11
    • 0034970031 scopus 로고    scopus 로고
    • A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
    • Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
    • (2001) Arthritis Rheum , vol.44 , pp. 1351-1358
    • Pope, J.E.1    Bellamy, N.2    Seibold, J.R.3
  • 12
    • 84863857123 scopus 로고    scopus 로고
    • Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database
    • Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1355-1360
    • Meier, F.M.1    Frommer, K.W.2    Dinser, R.3
  • 13
    • 0018887574 scopus 로고
    • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
    • Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
    • (1980) Arthritis Rheum , vol.23 , pp. 581-590
  • 15
    • 0042386341 scopus 로고    scopus 로고
    • European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score
    • Valentini G, D'Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
    • (2003) Ann Rheum Dis , vol.62 , pp. 904-905
    • Valentini, G.1    D'angelo, S.2    Della Rossa, A.3
  • 16
    • 34248379222 scopus 로고    scopus 로고
    • Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database
    • Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
    • (2007) Ann Rheum Dis , vol.66 , pp. 754-763
    • Walker, U.A.1    Tyndall, A.2    Czirjak, L.3
  • 17
    • 78650663333 scopus 로고    scopus 로고
    • Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma
    • Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011;70:104-9.
    • (2011) Ann Rheum Dis , vol.70 , pp. 104-109
    • Domsic, R.T.1    Rodriguez-Reyna, T.2    Lucas, M.3
  • 18
    • 0033767899 scopus 로고    scopus 로고
    • Severe organ involvement in systemic sclerosis with diffuse scleroderma
    • Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
    • (2000) Arthritis Rheum , vol.43 , pp. 2437-2444
    • Steen, V.D.1    Medsger, T.A.2
  • 19
    • 73849094087 scopus 로고    scopus 로고
    • Assessing the performance of prediction models: A framework for traditional and novel measures
    • Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-38.
    • (2010) Epidemiology , vol.21 , pp. 128-138
    • Steyerberg, E.W.1    Vickers, A.J.2    Cook, N.R.3
  • 20
    • 77954436578 scopus 로고    scopus 로고
    • Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database
    • Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37:1488-501.
    • (2010) J Rheumatol , vol.37 , pp. 1488-1501
    • Avouac, J.1    Walker, U.2    Tyndall, A.3
  • 21
    • 84863469731 scopus 로고    scopus 로고
    • Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis
    • Merkel PA, Silliman NP, Clements PJ, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012;64:3420-9.
    • (2012) Arthritis Rheum , vol.64 , pp. 3420-3429
    • Merkel, P.A.1    Silliman, N.P.2    Clements, P.J.3
  • 22
    • 73249139173 scopus 로고    scopus 로고
    • Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study
    • Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009;60:3821-30.
    • (2009) Arthritis Rheum , vol.60 , pp. 3821-3830
    • Su, T.I.1    Khanna, D.2    Furst, D.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.